Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Partmann who wrote (744)	12/4/1999 3:04:00 PM
From: Gary Korn	Read Replies (1) of 10345

12/3/99 Dow Jones News Serv. 02:17:00 Dow Jones News Service Copyright (c) 1999, Dow Jones & Company, Inc. Friday, December 3, 1999 Elan Pharmaceutical Releases Botulinum Toxin Phase 3 Results SO. SAN FRANCISCO, Calif. -(Dow Jones)- Elan Corp. PLC's (ELN) Elan Pharmaceuticals Inc. unit said two Phase 3 clinical trials found its Botulinum toxin Type B injectable solution may help some cervical dystonia patients. The two separate studies evaluated the drug's ability to decrease the pain, severity and disability of cervical dystonia, a movement disorder. In a press release, Elan Pharmaceuticals said it included the studies in a December 1998 product license application under review by the Food and Drug Administration. Side effects included dry mouth and difficulty swallowing and were generally mild to moderate. The Botulinum toxin Type B, which is injected directly into affected muscles, relaxes them by interrupting nerve transmissions. -Alan Paris; Dow Jones Newswires; 201-938-5400 ---- INDEX REFERENCES ----

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next